EACS2023: 677 Real-world effectiveness of cabotegravir + rilpivirine in virologically suppressed treatment experienced individuals in Europe: data from COMBINE-2 study A. Pozniak , G. Sridhar , L. Assoumou , L. Piroth , D. Braun , C. Fletcher , L. Ragone , A. Shah , J. van Wyk , V. Vannappagari The European Treatment Network for HIV, Hepatitis and Global Infectious Diseases (NEAT-ID), London, United Kingdom, ViiV Healthcare, Durham, United States, CHU Dijon-Bourgogne, Dijon Cedex, France, Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Research Organization (KC) Ltd., London, United Kingdom, GlaxoSmithKline, Brentford, Middlesex, United Kingdom, ViiV Healthcare, London, United Kingdom General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: Cabotegravir (CAB) + rilpivirine (RPV) is the first complete long-acting (LA) regimen for treatment experienced virologically suppressed (HIV-1 RNA <50 copies /mL) people with HIV (PWH) without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class. We assessed the virologic effectiveness among treatment experienced suppressed individuals initiating CAB+RPV LA in real-world settings in Europe. Method: Treatment experienced, virologically suppressed (HIV-1 RNA <50 copies/mL), adult PWH initiating CAB+RPV LA regimen between June 2021 and April 2023 were enrolled at NEAT ID Network sites across five countries in Europe. Viral loads (VLs) were assessed from first injection until CAB+RPV LA discontinuation or study end. Confirmed virologic failure (CVF) was defined as 2 consecutive VLs ≥200 copies/mL or 1 VL ≥200 copies/mL followed by discontinuation. Results: A total of 120 individuals received CAB+RPV LA injection in the study period. All individuals were treatment experienced, had VL <50 copies/mL at initiation, nine (7.5%) individuals had a prior history of virologic failure and four (3.3%) had history of NNRTI or INSTI mutations. The median age was 47 years (IQR: 39-54), 21 (17.5%) were females, 93 (77.5%) were white and 10 (8.3%) had BMI ≥30kg/m at initiation. 117 (97.5%) individuals remained on CAB+RPV LA over a median followup of 5.2 (IQR: 1.0, 10.8) months at the time of analysis. Among 89 individuals with VLs after first injection, the last VL measured was <50 copies/mL in 87 (97.8%) individuals and all follow-up VLs were <50 copies/mL in 96.6% (n=86). One individual had CVF with resistance mutations at failure and this participant switched to darunavir, cobicistat, emtricitabine and tenofovir alafenamide. Conclusions: This real-world data among PWH in Europe demonstrated high levels of virologic control after switching to CAB+RPV LA regimen among individuals virologically suppressed at initiation. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 2 1 3 4 5 2 6 7 2 1 2 3 4 5 6 7 2 148 19TH EUROPEAN AIDS CONFERENCE | WARSAW 2023
RkJQdWJsaXNoZXIy Mzc2ODc=